Drug intelligence / Profile preview

3,6-dihydroxy-xanthene-9-propionic acid

Development stage: Unknown
Modality: Small Molecules

Overview

3,6-dihydroxy-xanthene-9-propionic acid is a synthetic small molecule belonging to the class of aromatic heteropolycyclic compounds containing a xanthene moiety. It has been studied as an experimental compound and is not approved for clinical use. The compound acts as a noncompetitive inhibitor of human glutathione reductase (hGR), binding at a unique site in the enzyme's dimer interface and causing local structural changes that inhibit enzyme activity. This mechanism does not overlap with the glutathione binding site but prevents substrate binding through allosteric effects. Its potential utility lies in structure-based drug design targeting glutathione reductase[1][5].

Other names: 3-(3,6-dihydroxy-9H-xanthen-9-yl)propanoic acid

Targets

GSR (Glutathione reductase)

Beyond the preview

Go deeper on 3,6-dihydroxy-xanthene-9-propionic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3,6-dihydroxy-xanthene-9-propionic acid.

Explore the full profile